A5050471804- Influenza Virus Research Studies
- Respiratory viral infections research
- Immune Cell Function and Interaction
- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Monoclonal and Polyclonal Antibodies Research
- Long-Term Effects of COVID-19
- Viral gastroenteritis research and epidemiology
- Immunotherapy and Immune Responses
- vaccines and immunoinformatics approaches
- Animal Virus Infections Studies
- HIV Research and Treatment
- Immune Response and Inflammation
Janssen (Netherlands)
2015-2024
Johnson & Johnson (Netherlands)
2015-2018
The identification of human broadly neutralizing antibodies (bnAbs) targeting the hemagglutinin (HA) stem revitalized hopes developing a universal influenza vaccine. Using rational design and library approach, we engineered stable HA antigens ("mini-HAs") based on an H1 subtype sequence. Our most advanced candidate exhibits structural bnAb binding properties comparable to those full-length HA, completely protects mice in lethal heterologous heterosubtypic challenge models, reduces fever...
Safe and effective coronavirus disease–19 (COVID-19) vaccines are urgently needed to control the ongoing pandemic. While single-dose vaccine regimens would provide multiple advantages, two doses may improve magnitude durability of immunity protective efficacy. We assessed one- two-dose Ad26.COV2.S candidate in adult aged nonhuman primates (NHPs). A regimen induced higher peak binding neutralizing antibody responses compared with a single dose. In one-dose regimens, were stable for at least...
Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to evolve and recently emerging variants with substitutions in the Spike protein have led growing concerns over increased transmissibility decreased vaccine coverage due immune evasion. Here, sera from recipients of a single dose our Ad26.COV2.S COVID-19 were tested for neutralizing activity against several SARS-CoV-2 concern. All demonstrated susceptibility Ad26.COV2.S-induced serum neutralization albeit mainly...
Abstract The quantitation of antibody responses is a critical requirement for the successful development vaccines and therapeutics that often relies on use standardized reference materials to determine relative quantities within biological samples. validity comparing across assays using arbitrarily defined values therefore limited. We developed generalizable method known as MASCALE ( Ma ss S pectrometry Enabled C onversion A bsolute L evels E LISA Antibodies) absolute antibodies by...
Seasonal influenza vaccines are updated almost annually to match the antigenic drift in hemagglutinin (HA) surface glycoprotein. A new HA stem-based antigen, so-called "mini-HA," was recently shown induce cross-protective antibodies. However, cross-reactive antibodies targeting stem can also be found mice and humans after administration of seasonal vaccine. This has raised question whether similar conditions such a mini-HA would able show an increased breadth protection over immunization...
Seasonal vaccines are currently the most effective countermeasure against influenza. However, seasonal only strains closely related to influenza contained in vaccine. Recently a new hemagglutinin (HA) stem-based antigen, so-called "mini-HA", has been shown induce cross-protective immune response influenza-naive mice and non-human primates (NHP). prior exposure can have profound effect on subsequent infection protective efficacy of vaccination. Here we show that mini-HA, compared trivalent...
It remains important to develop the next generation of influenza vaccines that can provide protection against vaccine mismatched strains and be prepared for potential pandemic outbreaks. To achieve this, understanding immunological parameters mediate such broad is crucial.In current study we assessed contribution humoral cellular immune responses heterosubtypic H5N1 induced by a Matrix-M (MM) adjuvanted seasonal serum transfer T-cell depletion studies.We demonstrate MM partially mediated...
Abstract Seasonal influenza vaccines must be updated annually and suboptimally protect against strains mismatched to the selected vaccine strains. We previously developed a subunit antigen consisting of stabilized trimeric A group 1 hemagglutinin (H1) stem protein that elicits broadly neutralizing antibodies. Here, we further optimized stability manufacturability H1 (H1 v2, also known as INFLUENZA G1 mHA) characterized its formulation potency with different adjuvants in vitro animal models....